BioCentury | May 6, 2013
Company News

Novartis pharmaceuticals news

...and hypertension product Valturna aliskiren/valsartan , which Novartis withdrew from the U.S. market last year. Valturna...
BioCentury | Feb 4, 2013
Company News

Novartis cardiovascular news

...hypertension. Tekturna had $81 million in U.S. revenues in 4Q12. Last July, Novartis withdrew Valturna aliskiren/valsartan...
BioCentury | Apr 23, 2012
Company News

Novartis sales and marketing update

...Novartis will withdraw Valturna aliskiren/valsartan from the U.S. market, effective July 20. Valturna is indicated to...
...after 18-24 months vs. placebo plus SOC (see BioCentury, Jan. 2). Novartis said sales of Valturna...
...10% of the company's aliskiren sales. U.S. sales of aliskiren were $216 million in 2011. Valturna...
BioCentury | Oct 4, 2010
Finance

3Q approvals

...of gastrointestinal stromal tumors (GIST) after surgery Novartis AG (NYSE:NVS; SIX:NOVN) Withdraws MAA for Rasival aliskiren/valsartan...
BioCentury | Sep 20, 2010
Clinical News

Rasival aliskiren/valsartan regulatory update

...The European Medicines Agency (EMA) said Novartis withdrew an MAA for Rasival aliskiren/valsartan to treat hypertension...
...able to address requests from EMA's CHMP and provide additional data within the timeframe allowed. Rasival...
...the product as Valturna in the U.S. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Rasival aliskiren/valsartan...
BioCentury | Sep 18, 2010
Company News

Novartis withdraws EU application for aliskiren/valsartan

...The European Medicines Agency (EMA) said Novartis AG (NYSE:NVS; SIX:NOVN) withdrew an MAA for Rasival aliskiren/valsartan...
...to address requests from EMA's CHMP and provide additional data within the time frame allowed. Rasival...
...of Novartis' drugs: Tekturna / Rasilez aliskiren and Diovan valsartan. Novartis markets the product as Valturna...
BioCentury | Oct 5, 2009
Finance

3Q Approvals/3Q Setbacks

...to treat relapsing forms of multiple sclerosis (MS) Novartis AG (NYSE:NVS; SIX:NOVN) FDA approves Valturna aliskiren/valsartan...
BioCentury | Sep 28, 2009
Clinical News

Valturna regulatory update

...FDA approved an NDA from Novartis for Valturna aliskiren/valsartan to treat hypertension in patients not adequately...
...II receptor (type AT1) antagonist, individually. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Valturna ( aliskiren/valsartan...
BioCentury | Jul 27, 2009
Clinical News

Aliskiren/valsartan combination regulatory update

...an angiotensin II receptor (type AT1) antagonist, separately. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Aliskiren/valsartan...
BioCentury | Feb 2, 2009
Clinical News

Aliskiren/valsartan combination regulatory update

...an angiotensin II receptor (type AT1) antagonist, individually. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Product: Aliskiren/valsartan...
Items per page:
1 - 10 of 10